Company profile
SAB BIOTHERAPEUTICS, INC.
NASDAQ:SABSBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SAB-176 | phase2 | — | 2 | no active trials |
| SAB-185 | phase1 | — | 2 | completed, unknown |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06435936 | phase1 | unknown | 2024-04-22 | 2025-02-01 | SAb Biotherapeutics, Inc. | A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo |
| NCT07187531 | phase2 | recruiting | 2025-11-25 | 2027-11-01 | SAb Biotherapeutics, Inc. | SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes |
| NCT04471038 | phase1 | completed | 2020-07-29 | 2021-04-19 | SAb Biotherapeutics, Inc. | Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants |
| NCT04469179 | phase1 | unknown | 2020-08-20 | 2021-02-25 | SAb Biotherapeutics, Inc. | Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19 |
| NCT04468958 | phase1 | completed | 2020-07-01 | 2020-12-23 | SAb Biotherapeutics, Inc. | Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants |
FDA applications (0)
No records yet.